ASCO大会备受关注的研究有哪些？
撰文 | 玖陆2023年美国临床肿瘤学会（ASCO）会议将在美国时间6月2日-6日在芝加哥召开。作为全球规模最大的肿瘤领域学术会议，世界一流的肿瘤学专家齐聚一堂，将国际最前沿的临床肿瘤学研究成果和治疗技术分享给参会者。对于肿瘤学者，ASCO年会是绝对不容错过的学术交流盛会。
日前，摘要标题已公布。小编特此整理入选全体大会的研究，以飨读者。
早期乳腺癌迎来辅助治疗新结果
1、瑞波西利联合内分泌治疗辅助治疗HR+/HER2−早期乳腺癌患者店的III期NATALEE试验。Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer.摘要：LBA500
讲者：Dennis J. Slamon, MD, PhD | David Geffen School of Medicine at University of California Los Angeles
2、monarchE年龄相关有效性和安全性研究：阿贝西利联合内分泌辅助治疗HR+，HER2-，淋巴结阳性，高危早期乳腺癌（EBC）患者。Efficacy and safety results by age in monarchE: Adjuvant abemaciclib combined with endocrine therapy (ET) in patients with HR+, HER2-, node-positive, high-risk early breast cancer (EBC).摘要：501
讲者： Erika P. Hamilton, MD | Sarah Cannon Research Institute, Tennessee Oncology
3、新辅助化疗和手术后检测ct DNA，以此预测 ER+和HER2-乳腺癌的早期复发：PENELOPE-B 试验分析。Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial.摘要：502
讲者：Nicholas C. Turner, MD, PhD | The Institue of Cancer Research, Royal Cancer Hospital
4、绝经前接受卵巢功能抑制和消融治疗后的乳腺癌复发和生存影响，来自14项随机试验的99325例女性的患者水平荟萃分析。Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 women in 25 randomized trials.摘要：503
讲者：Richard G. Gray | University of Oxford
5、PAM50复发风险评分系统在绝经前早期HR+乳腺癌患者的评估：SOFT试验的二次分析。Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR+ breast cancer: A secondary analysis of the SOFT trial.摘要：504
讲者：Lauren Claire Brown, MBChB | Peter MacCallum Cancer Centre
6、HR+/HER2-年轻乳腺癌的肿瘤浸润淋巴细胞 （TIL） 的临床病理特征和预后关系。Association of tumor-infiltrating lymphocytes (TILs) with clinicopathologic characteristics and prognosis in young women with HR+/HER2- breast cancer (BC).摘要：505
讲者：Megan E Tesch, MD | Dana-Farber Cancer Institute
7、PHERGain II期随机研究：降阶梯化疗在HER2+早期乳腺癌患者中的3年iDFS疗效3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC).摘要：LBA506
讲者：Javier Cortes, MD, PhD | International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain, Medica Scientia Innovation Research (MEDSIR), Barcelona, Spain, Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine
8、新辅助免疫化疗在sTIL高和sTIL低三阴性乳腺癌（TNBC）的不同增殖特征对疗效的影响：NeoPACT试验的生物标志物分析。Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial.摘要：507
讲者：Shane R Stecklein, MD | University of Kansas Medical Center
9、TILs可否预测曲妥珠单抗治疗HER2+乳腺癌的益处？来自5项试验4097女性患者的荟萃分析。Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.摘要：508
讲者：Robert Kerrin Hills, MA MSc DPhil | University of Oxford
转移性乳腺癌内分泌治疗新格局
1、SONIA试验（BOOG 2017-03）III期主要结局分析，CDK4/6抑制剂治疗HR+，HER2-晚期乳腺癌（ABC）最佳治疗时间。Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC).摘要：LBA1000
讲者：Gabe S. Sonke, MD, PhD | The Netherlands Cancer Institute
2、HR+/HER2-晚期乳腺癌（ABC）患者的二线内分泌治疗伴或不伴哌柏西利维持治疗：PALMIRA 试验。Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial.摘要：1001
讲者：Antonio Llombart-Cussac, MD | Hospital Arnau de Vilanova, Universidad Católica de Valencia, Medica Scientia Innovation Research (MEDSIR), Barcelona
3、PADA-1随机试验：芳香酶抑制剂或氟维司群联合哌柏西利治疗是ESR1突变动态监测。Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial.摘要：1002
讲者：Francois Clement Bidard, MD, PhD | Institut Curie
4、TROPiCS-02 III期试验：戈沙妥珠单抗在HR+/HER2–转移性乳腺癌中的最终总生存期分析。Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC).摘要：1003
讲者：Sara M. Tolaney, MD, MPH | Department of Medical Oncology, Dana-Farber Cancer Institute
5、 HER3-DXd治疗转移性乳腺癌的II期研究。A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC).摘要：1004
讲者：Erika P. Hamilton, MD | Sarah Cannon Research Institute, Tennessee Oncology, PLLC
6、三阴性乳腺癌患者HER2-低水平动态监测：重复活检的影响。Dynamic HER2-low status among patients with triple negative breast cancer (TNBC): The impact of repeat biopsies.摘要：1005
讲者：Yael Bar, MD, PhD | Massachusetts General Hospital
7、DESTINY-Breast01, -02, and -03：T-DXd治疗HER2+乳腺癌的年龄特异性汇总分析。An age-specific pooled analysis of trastuzumab deruxtecan (TDXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03.摘要：1006
讲者：Barbara Pistilli, MD | Breast Cancer Unit, Gustave Roussy
8、固定剂量卡培他滨与标准剂量卡培他滨在转移性乳腺癌中的随机试验：X-7/7试验。Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial.摘要：1007
讲者：Qamar J. Khan, MD | University of Kansas Cancer Center
9、采用CANKADO PRO-React eHealth管理系统，对接受哌柏西利和内分泌治疗的HR+/ HER2-转移性乳腺癌患者疗效和生活质量恶化时间的影响：多中心随机PreCycle试验的主要结局分析。CANKADO PRO-React eHealth support in patients with HR+ HER2- metastatic breast cancer receiving palbociclib and endocrine therapy and the affect on time to deterioration of quality of life: Primary outcome analysis of the multicenter randomized PreCycle trial.摘要：1008
讲者：Nadia Harbeck, MD, PhD | Breast Center, Department of Obstetrics and Gynecology and CCC Munich, LMU University Hospital
乳腺癌免疫前景，四项研究入选临床科学研讨会
1、AURORA 研究中匹配的原发性和转移性乳腺癌病变中免疫微环境的表征：BIG 14-01。Characterization of the immune microenvironment in matched primary and metastatic breast cancer lesions from the AURORA study: BIG 14-01.摘要：1009
讲者：Florentine Hilbers, PhD | Department of Molecular Pathology, Netherlands Cancer Institute
2、接受微管靶向药物治疗的转移性乳腺癌（MBC）中TIL数量和生存率的关系：CALGB 40502事后分析。Association of tumor infiltrating lymphocyte quantity with survival in patients (pts) with metastatic breast cancer (MBC) receiving microtubule-targeting agents: Post hoc analysis CALGB 40502 (Alliance).摘要：1010
讲者：Daniel G. Stover, MD | Ohio State University Comprehensive Cancer Center
3、外周免疫细胞RNA表达水平， 一种用于预测治疗效果的微创液体活检，预测GeparNuevo试验中三阴性乳腺癌的生存率和免疫不良反应时间。RNA expression levels from peripheral immune cells, a minimally invasive liquid biopsy source to predict response to therapy, survival and immune-related adverse events in patients with triple negative breast cancer enrolled in the GeparNuevo trial.摘要：1011
讲者:Hanna Hübner, PhD | Department of Gynaecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN)
4、BRACELET-1 （PrE0113）：溶瘤病毒联合紫衫醇和avelumab诱导HR+/HER2-转移性乳腺癌的炎症表型。BRACELET-1 (PrE0113): Inducing an inflammatory phenotype in metastatic HR+/HER2- breast cancer with the oncolytic reovirus pelareorep in combination with paclitaxel and avelumab.摘要：1012
讲者:Amy Sanders Clark, MD, MSCE | University of Pennsylvania
小结
在今年ASCO大会上，口头报道和临床科学研讨会包括早期、局部、转移性乳腺癌的研究。其中，对于转移性乳腺癌，探索了ADC药物最佳治疗时间，卡培他滨的剂量对治疗效果的影响等内容，此次ASCO会议的报道将会对乳腺癌治疗带来重要的用药参考价值。
为了向临床医生传递肿瘤领域的新观念、新知识和新技术，鼓励和支持我国临床肿瘤医学研究与创新，医学界传媒将紧跟ASCO会议学术热点，通过线下参会、国内外专家交流、大会解读报道、大咖观点分享等形式来全面展现会议最新内容。
精彩资讯等你来责任编辑：Sheep
*医学界力求其发表内容专业、可靠，但不对内容的准确性做出承诺；请相关各方在采用或以此作为决策依据时另行核查。
